Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Letaxaban. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 known ✓ | P00742 | 20/20 | 1.00 |
| ▸ | F2 | P00734 | 2/20 | 1.00 |
| ▸ | F9 | P00740 | 1/20 | 1.00 |
| ▸ | PLAT | P00750 | 1/20 | 1.00 |
| ▸ | KLKB1 | P03952 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Letaxaban SCHEMBL2855505 | 1.00 | F10 (1.00) | F10F2F9PLATKLKB1 | |
| Letaxaban SCHEMBL766143 | 1.00 | F10 (1.00) | F10F2F9PLATKLKB1 | |
| Letaxaban SCHEMBL2855504 | 1.00 | F10 (1.00) | F10F2F9PLATKLKB1 | |
| SCHEMBL2862509 | 0.95 | F10 (1.00) | F10F2F9PLATKLKB1 | |
| SCHEMBL2854445 | 0.87 | F10 (1.00) | F10F2F9PLATKLKB1 | |
| SCHEMBL2854447 | 0.87 | F10 (1.00) | F10F2F9PLATKLKB1 | |
| SCHEMBL2858092 | 0.87 | F10 (1.00) | F10F2F9PLATKLKB1 | |
| SCHEMBL1156987 | 0.86 | F10 (1.00) | F10F2F9PLATKLKB1 | |
| SCHEMBL13303264 | 0.86 | F10 (0.77) | F10F2F9PLATKLKB1 | |
| SCHEMBL2862268 | 0.86 | F10 (1.00) | F10F2F9PLATKLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 367 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605371-B2 | Combination therapy for cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-04-21 | — | — | US | claimed |
| US-20260083773-A1 | PEGYLATED MENAQUINOL COMPOSITIONS AND METHODS OF TREATMENT | EPIZON PHARMA INC (US) | 2026-03-26 | — | — | US | claimed |
| US-12514871-B2 | Pegylated menaquinol compositions and methods of treatment | Epizon Pharma, Inc. (US) | 2026-01-06 | — | — | US | claimed |
| WO-2025150072-A1 | A STABLE ORAL PRO-DISPERSION FORMULATION AND IMPLEMENTATIONS THEREOF | PULSE PHARMACEUTICALS PVT LTD (IN) | 2025-07-17 | — | — | WO | claimed |
| US-20250186563-A1 | UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | ALEXION PHARMA INC (US) | 2025-06-12 | — | — | US | claimed |
| US-20250064891-A1 | HOST PROTEASES ESSENTIAL FOR PARAINFLUENZA SPREAD IN THE HUMAN LUNG: POTENTIAL TARGETS FOR ANTIVIRAL INTERVENTIONS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2025-02-27 | — | — | US | claimed |
| EP-4493183-A2 | TRANSDERMAL DELIVERY SYSTEMS FOR CERTAIN FACTOR XA INHIBITORS AND RELATED METHODS FOR THEIR PREPARATION AND USE | Arx, LLC (US) | 2025-01-22 | — | — | EP | claimed |
| US-12029755-B2 | Carbon monoxide-based therapies and implantable devices for the treatment of vascular disease | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-07-09 | — | — | US | claimed |
| US-20240197747-A1 | TREATMENT OF VIRAL INFECTIONS WITH COMBINATION OF PIKFYVE KINASE INHIBITORS AND TMPRSS-2 INHIBITORS | AcuraStem, Inc. (US) | 2024-06-20 | — | — | US | claimed |
| US-20240189317-A1 | ANTIVIRAL COMPOSITIONS AND METHODS | ACADIA WOODS PARTNERS, LLC | 2024-06-13 | — | — | US | claimed |
| US-20230000957-A1 | UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | PORTOLA PHARMACEUTICALS, LLC | 2023-01-05 | — | — | US | claimed |
| US-11524978-B2 | Synthetic peptides, pharmaceutical compositions comprising the same, and uses thereof in treating thromboembolism-related diseases | ACADEMIA SINICA (TW) | 2022-12-13 | — | — | US | claimed |
| WO-2022197667-A1 | ANTIVIRAL COMPOSITIONS AND METHODS | YOUNG PETER R (US) | 2022-09-22 | — | — | WO | claimed |
| WO-2022133182-A1 | METHOD OF TREATING CORONAVIRUS INFECTION | CHAN ZUCKERBERG BIOHUB, INC. (US) | 2022-06-23 | — | — | WO | claimed |
| US-20220160756-A1 | CARBON MONOXIDE-BASED THERAPIES AND IMPLANTABLE DEVICES FOR THE TREATMENT OF VASCULAR DISEASE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-05-26 | — | — | US | claimed |
| US-20220146538-A1 | METHOD AND DEVICE FOR DETECTING COAGULATION FACTOR INHIBITORS AND ANTIPLATELETS IN A SAMPLE | SPANO JOSEPH LOUIS (US) | 2022-05-12 | — | — | US | claimed |
| US-11318331-B2 | Pulmonary hypertension treatment | SONIVIE LTD. (IL) | 2022-05-03 | — | — | US | claimed |
| WO-2022056326-A1 | ANTICOAGULANT COMPOUNDS, METHODS AND DEVICES FOR OPHTHALMIC USE | ELIXIR MEDICAL CORPORATION (US) | 2022-03-17 | — | — | WO | claimed |
| WO-2022031758-A1 | ANTICOAGULANT COMPOUNDS AND METHODS AND DEVICES FOR THEIR PULMONARY USE | ELIXIR MEDICAL CORPORATION (US) | 2022-02-10 | — | — | WO | claimed |
| WO-2022026398-A1 | COMBINATION THERAPY FOR CANCER | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-02-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240189317-A1 | ANTIVIRAL COMPOSITIONS AND METHODS | PIKFYVE, APAF1, API5 | F10 1288/4885F2 600/4885F9 2915/4885 |
| US-20250186563-A1 | UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | SERPINC1, F8, F9 | F10 6/4885F2 4/4885F9 3/4885 |
| US-20220160756-A1 | CARBON MONOXIDE-BASED THERAPIES AND IMPLANTABLE DEVICES FOR THE TREATMENT OF VASCULAR DISEASE | MB, VCAM1, NOS2 | F10 1574/4885F2 650/4885F9 392/4885 |
| US-12029755-B2 | Carbon monoxide-based therapies and implantable devices for the treatment of vascular disease | MB, VCAM1, NOS2 | F10 1574/4885F2 650/4885F9 392/4885 |
| US-20240197747-A1 | TREATMENT OF VIRAL INFECTIONS WITH COMBINATION OF PIKFYVE KINASE INHIBITORS AND TMPRSS-2 INHIBITORS | PIKFYVE, TMPRSS2, TMPRSS4 | F10 3266/4885F2 1292/4885F9 1907/4885 |
| US-20230000957-A1 | UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | SERPINC1, F8, F9 | F10 6/4885F2 4/4885F9 3/4885 |
| US-20260083773-A1 | PEGYLATED MENAQUINOL COMPOSITIONS AND METHODS OF TREATMENT | SGMS1, SGMS2, MEN1 | F10 1095/4885F2 254/4885F9 851/4885 |
| US-12605371-B2 | Combination therapy for cancer | BRAF, TFPI, HGFAC | F10 42/4885F2 39/4885F9 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.